Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Trial Comparing Amrubicin Versus Topotecan as Second-Line Treatment in Patients With Extensive Small Cell Lung Cancer Sensitive to First-Line Chemotherapy

NCT00319969 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00319969
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00319969 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Trial Comparing Amrubicin Versus Topotecan as Second-Line Treatment in Patients With Extensive Small Cell Lung Cancer Sensitive to First-Line Chemotherapy
Lead sponsor
Celgene Corporation
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2006
Completion date
January 31, 2009
Enrollment
76 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer